-
公开(公告)号:US20100324017A1
公开(公告)日:2010-12-23
申请号:US12526250
申请日:2008-02-06
IPC分类号: A61K31/403 , C07D209/88 , C07D401/04 , C07D405/04 , C07D403/04 , C07D405/06 , C07D413/06 , C07D409/04 , C07D495/04 , A61K31/4439 , A61K31/5377 , A61P25/18 , A61P25/28 , A61P25/00
CPC分类号: C07D401/04 , C07D209/88 , C07D401/06 , C07D401/14 , C07D403/04 , C07D403/06 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/06 , C07D409/14 , C07D413/06 , C07D471/04 , C07D491/048 , C07D495/04
摘要: An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia and the like, based on the 5-HT5A receptor modulating action. It was confirmed that a compound characterized by a structure that a tricyclic hetero ring having a pyrrole ring at the center and guanidine are bonded via a carbonyl group has a potent 5-HT5A receptor modulating action and an excellent pharmacological action based thereon, and thus, it was found that the compound can be an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder, particularly for memory-related functional disorders such as cognitive impairments including dementia and schizophrenia, thereby completing the present invention.
摘要翻译: 本发明的目的是提供一种基于5-HT5A受体调节作用治疗或预防痴呆,精神分裂症等的新颖且优异的药剂。 证实了具有中心具有吡咯环的三环杂环和胍通过羰基键合的结构的化合物具有有效的5-HT5A受体调节作用和基于其的优异的药理作用,因此, 发现该化合物可以是用于治疗或预防痴呆,精神分裂症,双相情感障碍或注意缺陷多动障碍,特别是用于记忆相关功能障碍如认知障碍包括痴呆和精神分裂症的优良药剂,从而完成本发明。
-
公开(公告)号:US20110207729A1
公开(公告)日:2011-08-25
申请号:US12672277
申请日:2008-08-07
申请人: Isao Kinoyama , Satoshi Miyamoto , Takehiro Miyazaki , Yohei Koganemaru , Yuichiro Kawamoto , Nobuyuki Shiraishi , Hiroaki Hoshii , Akio Kuroda , Mayako Yamazaki , Minoru Yasuda , Hiroaki Mizuno
发明人: Isao Kinoyama , Satoshi Miyamoto , Takehiro Miyazaki , Yohei Koganemaru , Yuichiro Kawamoto , Nobuyuki Shiraishi , Hiroaki Hoshii , Akio Kuroda , Mayako Yamazaki , Minoru Yasuda , Hiroaki Mizuno
IPC分类号: A61K31/5377 , C07D311/04 , C07D405/12 , C07D413/12 , C07D311/96 , C07D405/04 , C07D407/10 , A61K31/352 , A61K31/4155 , A61K31/496 , A61K31/4433 , A61K31/357 , A61P25/00 , A61P25/18 , A61P25/28
CPC分类号: C07D295/12 , C07C279/22 , C07C317/44 , C07C2601/02 , C07C2602/10 , C07C2602/12 , C07D213/56 , C07D213/61 , C07D213/64 , C07D215/12 , C07D231/12 , C07D239/26 , C07D241/12 , C07D261/08 , C07D277/30 , C07D295/155 , C07D307/52 , C07D307/54 , C07D309/04 , C07D311/04 , C07D311/58 , C07D313/08 , C07D319/18 , C07D333/24 , C07D333/54 , C07D333/56 , C07D335/06 , C07D405/04 , C07D407/04 , C07D409/04 , C07D471/04
摘要: An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia, and the like, based on the serotonin 5-HT5A receptor modulating action.It was confirmed that a bicyclic acylguanidine derivative which has a characteristic structure that guanidine is bonded to one ring of a bicyclic structure such as chromene and dihydronaphthalene through a carbonyl group and a cyclic group is bonded on the other ring, has a potent 5-HT5A receptor modulating action and an excellent pharmacological action based on this mechanism. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder.
摘要翻译: 本发明的目的是提供一种用于治疗或预防基于5-羟色胺5-HT5A受体调节作用的痴呆,精神分裂症等的新颖且优异的药剂。 证实具有特征性结构的双环酰基胍衍生物具有有效的5-HT5A(其具有通过羰基和环状基团键合在一个双环结构的环上,如色烯和二氢萘结合在另一个环上) 受体调节作用和基于该机制的优异的药理作用。 本发明可用作治疗或预防痴呆,精神分裂症,双相情感障碍或注意缺陷多动障碍的优良药剂。
-
公开(公告)号:US08853242B2
公开(公告)日:2014-10-07
申请号:US13388872
申请日:2010-08-05
IPC分类号: A61K31/472 , A61K31/47 , A61K31/4709 , A61P25/00 , A61P25/18 , A61P25/28 , C07D215/48 , C07D215/60 , C07D217/14 , C07D215/54 , C07D217/02 , C07D217/22 , C07D217/16 , C07D401/04
CPC分类号: C07D215/48 , C07D215/54 , C07D215/60 , C07D217/02 , C07D217/14 , C07D217/16 , C07D217/22 , C07D401/04
摘要: [Object] An excellent agent for preventing or treating dementia, schizophrenia, and the like, based on serotonin 5-HT5A receptor modulating action, is provided.[Means for Solution] It was confirmed that acylguanidine derivatives (the following formula I; any one of Z1, Z2, Z3, Z4 and Z5 is nitrogen atom, and the others are carbon atoms) which have the characteristic structure in which the guanidine is bonded to one ring of the quinoline or isoquinoline via a carbonyl group, and a cyclic group is bonded to the other ring, exhibit potent 5-HT5A receptor modulating actions and excellent pharmacological actions based on the 5-HT5A receptor modulating action, and thus can be excellent agents for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder. Thus, the present invention has been completed.
摘要翻译: 提供了一种基于5-羟色胺5-HT5A受体调节作用预防或治疗痴呆,精神分裂症等的优异剂。 [解决方案]确认酰基胍衍生物(下式I,Z 1,Z 2,Z 3,Z 4和Z 5中的任一个为氮原子,其余为碳原子),其特征在于胍 通过羰基键合到喹啉或异喹啉的一个环上,并且环状基团与另一个环键合,表现出基于5-HT5A受体调节作用的有效的5-HT5A受体调节作用和优异的药理作用,因此可以 是预防或治疗痴呆,精神分裂症,双相情感障碍或注意缺陷多动障碍的优良药剂。 因此,本发明已经完成。
-
公开(公告)号:US20120142727A1
公开(公告)日:2012-06-07
申请号:US13388872
申请日:2010-08-05
IPC分类号: A61K31/472 , C07D217/14 , C07D215/60 , A61P25/00 , A61K31/4709 , A61P25/28 , A61P25/18 , C07D215/48 , A61K31/47
CPC分类号: C07D215/48 , C07D215/54 , C07D215/60 , C07D217/02 , C07D217/14 , C07D217/16 , C07D217/22 , C07D401/04
摘要: [Object] An excellent agent for preventing or treating dementia, schizophrenia, and the like, based on serotonin 5-HT5A receptor modulating action, is provided.[Means for Solution] It was confirmed that acylguanidine derivatives (the following formula I; any one of Z1, Z2, Z3, Z4 and Z5 is nitrogen atom, and the others are carbon atoms) which have the characteristic structure in which the guanidine is bonded to one ring of the quinoline or isoquinoline via a carbonyl group, and a cyclic group is bonded to the other ring, exhibit potent 5-HT5A receptor modulating actions and excellent pharmacological actions based on the 5-HT5A receptor modulating action, and thus can be excellent agents for preventing or treating dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder. Thus, the present invention has been completed.
摘要翻译: 提供了一种基于5-羟色胺5-HT5A受体调节作用预防或治疗痴呆,精神分裂症等的优异剂。 [解决方案]确认酰基胍衍生物(下式I,Z 1,Z 2,Z 3,Z 4和Z 5中的任一个为氮原子,其余为碳原子),其特征在于胍 通过羰基与喹啉或异喹啉的一个环键合,并且环状基团与另一个环键合,表现出基于5-HT5A受体调节作用的有效的5-HT5A受体调节作用和优异的药理作用,因此可以 是预防或治疗痴呆,精神分裂症,双相情感障碍或注意缺陷多动障碍的优良药剂。 因此,本发明已经完成。
-
公开(公告)号:US20120041036A1
公开(公告)日:2012-02-16
申请号:US13148448
申请日:2010-02-08
IPC分类号: A61K31/166 , C07D213/57 , A61K31/4418 , C07D277/30 , A61P25/00 , C07C317/50 , C07D309/22 , A61K31/351 , A61P25/28 , A61P25/18 , C07C237/48 , A61K31/426
CPC分类号: C07C279/22 , C07C317/44 , C07C323/62 , C07C2601/02 , C07D213/58 , C07D213/61 , C07D277/20 , C07D277/56 , C07D307/28 , C07D309/22
摘要: An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on serotonin 5-HT5A receptor modulating action.It was discovered that acylguanidine derivatives, in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent the 5-HT5A receptor modulating action and excellent pharmacological actions based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.
摘要翻译: 本发明的目的是提供一种用于治疗或预防基于5-羟色胺5-HT5A受体调节作用的痴呆,精神分裂症的优异剂。 发现通过羰基和环状基团将胍结合到萘环上的酰基胍衍生物与另一个环键合,表现出5-HT5A受体调节作用的有效作用和基于 那个行动。 本发明可用作治疗或预防痴呆,精神分裂症,双相情感障碍或注意缺陷多动障碍的优良剂。
-
公开(公告)号:US20110306621A1
公开(公告)日:2011-12-15
申请号:US13148379
申请日:2010-02-08
申请人: Isao Kinoyama , Takehiro Miyazaki , Yohei Koganemaru , Nobuyuki Shiraishi , Yuichiro Kawamoto , Takuya Washio
发明人: Isao Kinoyama , Takehiro Miyazaki , Yohei Koganemaru , Nobuyuki Shiraishi , Yuichiro Kawamoto , Takuya Washio
IPC分类号: A61K31/505 , C07D213/64 , C07D277/30 , C07D213/56 , C07D309/22 , C07D319/18 , C07D333/24 , C07D215/14 , C07D217/04 , C07D217/16 , C07D239/26 , A61K31/166 , A61K31/277 , A61K31/44 , A61K31/426 , A61K31/351 , A61K31/357 , A61K31/381 , A61K31/47 , A61K31/472 , A61P25/28 , A61P25/00 , A61P25/18 , C07C279/22
CPC分类号: C07C279/22 , C07D209/18 , C07D213/56 , C07D213/58 , C07D213/60 , C07D213/61 , C07D213/64 , C07D213/68 , C07D213/84 , C07D215/14 , C07D217/02 , C07D231/12 , C07D231/16 , C07D239/26 , C07D239/28 , C07D263/56 , C07D271/04 , C07D271/06 , C07D271/10 , C07D271/12 , C07D277/20 , C07D277/30 , C07D277/64 , C07D307/16 , C07D307/80 , C07D309/22 , C07D317/42 , C07D317/60 , C07D317/62 , C07D319/18 , C07D333/08 , C07D333/24 , C07D333/28 , C07D333/38
摘要: An object of the present invention is to provide an excellent agent for treating or preventing dementia, schizophrenia based on a serotonin 5-HT5A receptor modulating action.It was confirmed that acylguanidine derivatives, which has the characteristic structure in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent 5-HT5A receptor modulating action and excellent pharmacological action based on the action. The present invention is useful as an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder or attention deficit hyperactivity disorder.
摘要翻译: 本发明的目的是提供一种用于治疗或预防基于5-羟色胺5-HT5A受体调节作用的痴呆,精神分裂症的优异剂。 确认了具有通过羰基和环状基团将胍键合到萘的特征结构的酰基胍衍生物与另一个环结合,表现出有效的5-HT5A受体调节作用,优异的 基于行动的药理作用。 本发明可用作治疗或预防痴呆,精神分裂症,双相情感障碍或注意缺陷多动障碍的优良剂。
-
公开(公告)号:US20130166989A1
公开(公告)日:2013-06-27
申请号:US13642146
申请日:2010-07-08
申请人: Takehiro Miyazaki
发明人: Takehiro Miyazaki
IPC分类号: H03M13/05
CPC分类号: H03M13/05 , F02D41/26 , F02D2041/228 , G06F21/57 , G06F21/64 , H03M13/09 , H03M13/11 , H04L1/0057 , H04L1/0061
摘要: Disclosed is a vehicle data abnormality determination device including a storage unit for pre-storing a 2-byte remainder term which is a result of a CRC arithmetic operation on a target area for arithmetic operations in a predetermined memory area, and an arithmetic operation unit for performing a CRC arithmetic operation while including the 2-byte remainder term in this CRC arithmetic operation. Because when performing the CRC arithmetic operation, the vehicle data abnormality determination device performs the CRC arithmetic operation while including the 2-byte remainder term in this CRC arithmetic operation after performing an arithmetic operation on the target area, the vehicle data abnormality determination device always makes the computed result be zero when the data has not been falsified, and can detect whether or not the data has been falsified easily and properly.
摘要翻译: 本发明公开了一种车辆数据异常判定装置,其特征在于,包括:存储部,其将预定存储区域中的算术运算对象区域的CRC算术运算结果的2字节剩余项预先存储;以及算术运算单元, 在该CRC算术运算中包括2字节余数项,执行CRC算术运算。 由于在执行CRC算术运算时,车辆数据异常判定装置在对该目标区域进行算术运算后,在该CRC运算中包括2字节的余数项,进行CRC运算运算,车辆数据异常判定装置始终进行 当数据没有被伪造时,计算结果为零,并且可以检测数据是否已被轻易正确地伪造。
-
公开(公告)号:US09172398B2
公开(公告)日:2015-10-27
申请号:US13642146
申请日:2010-07-08
申请人: Takehiro Miyazaki
发明人: Takehiro Miyazaki
IPC分类号: H03M13/00 , H03M13/05 , H03M13/09 , H03M13/11 , F02D41/26 , G06F21/64 , H04L1/00 , F02D41/22
CPC分类号: H03M13/05 , F02D41/26 , F02D2041/228 , G06F21/57 , G06F21/64 , H03M13/09 , H03M13/11 , H04L1/0057 , H04L1/0061
摘要: Disclosed is a vehicle data abnormality determination device including a storage unit for pre-storing a 2-byte remainder term which is a result of a CRC arithmetic operation on a target area for arithmetic operations in a predetermined memory area, and an arithmetic operation unit for performing a CRC arithmetic operation while including the 2-byte remainder term in this CRC arithmetic operation. Because when performing the CRC arithmetic operation, the vehicle data abnormality determination device performs the CRC arithmetic operation while including the 2-byte remainder term in this CRC arithmetic operation after performing an arithmetic operation on the target area, the vehicle data abnormality determination device always makes the computed result be zero when the data has not been falsified, and can detect whether or not the data has been falsified easily and properly.
摘要翻译: 本发明公开了一种车辆数据异常判定装置,其特征在于,包括:存储部,其将预定存储区域中的算术运算对象区域的CRC算术运算结果的2字节剩余项预先存储;以及算术运算单元, 在该CRC算术运算中包括2字节余数项,执行CRC算术运算。 由于在执行CRC算术运算时,车辆数据异常判定装置在对该目标区域进行算术运算后,在该CRC运算中包括2字节的余数项,进行CRC运算运算,车辆数据异常判定装置始终进行 当数据没有被伪造时,计算结果为零,并且可以检测数据是否已被轻易正确地伪造。
-
-
-
-
-
-
-